<code id='3D81AF1D1F'></code><style id='3D81AF1D1F'></style>
    • <acronym id='3D81AF1D1F'></acronym>
      <center id='3D81AF1D1F'><center id='3D81AF1D1F'><tfoot id='3D81AF1D1F'></tfoot></center><abbr id='3D81AF1D1F'><dir id='3D81AF1D1F'><tfoot id='3D81AF1D1F'></tfoot><noframes id='3D81AF1D1F'>

    • <optgroup id='3D81AF1D1F'><strike id='3D81AF1D1F'><sup id='3D81AF1D1F'></sup></strike><code id='3D81AF1D1F'></code></optgroup>
        1. <b id='3D81AF1D1F'><label id='3D81AF1D1F'><select id='3D81AF1D1F'><dt id='3D81AF1D1F'><span id='3D81AF1D1F'></span></dt></select></label></b><u id='3D81AF1D1F'></u>
          <i id='3D81AF1D1F'><strike id='3D81AF1D1F'><tt id='3D81AF1D1F'><pre id='3D81AF1D1F'></pre></tt></strike></i>

          Home / knowledge / hotspot

          hotspot


          hotspot

          author:fashion    Page View:5
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In